MDXG Mimedx Group Inc

$MDXG I think it’s unreasonable to assume that the Sanara deal will not going through. It is well within the FTC’s protocol to seek additional information , most probably specifically anti trust clarification. Although one wonders why the information wasn’t provided the first time? BIG PICTURE: Assuming positive acquisition outcome, Sanara posted $25.9M first quarter , 18.6% greater than ‘25. MDXG posted $59M ( CMS reimbursement reduction) . Were Sanara ( the surgical engine ) to post similar increases next three quarters , or annual revenue of $119.4M and even if MDXG ( increasingly wound engine ) remains flat or $240M , we are looking at a very conservatively $360M entity that is profitable with $140M cash as of last call. We will continue to be tormented by this “ can’t shoot straight “ company , but the ammunition is high quality and the gun is pointed straight at the target. Just need the marksman to deliver. Best to all.

$MDXG Huge drop in short interest – down 1,397,804 shares…so, a reversal from two weeks ago.

$MDXG 3 near term catalysts. Deal closure, Medicare pricing change, and now lawsuit settlements.

$MDXG Mdxg middle of guidance (275m), at 5X multiple (low end for surgical), places mkt cap at more than double current mkt cap. If deal happens, 400m estimate, at 5X multiple, quadruples current mkt cap.

$MDXG anyone have any insight into potential recoveries from other two patent lawsuits? Capper said they were larger ongoing litigations. Sure would be a pleasant surprise to settle and receive $50-$100MM more in damages from competitors who violated our patents! Damages aka license agreements.

$MDXG Earnings in 2 weeks, seems earlier than usual. Capper has been silent since last ER. Makes me very worried.

$MDXG In one Arizona case, the owners of two wound care companies pleaded guilty to more than $1.2 billion in fraudulent claims. Medicare paid over $1 million per patient for grafts slapped on elderly patients who didn't need them, many of them dying in hospice. In June, DOJ charged 11 more defendants over more than $2 billion in allograft claims, including a company accused of issuing sham invoices to inflate what Medicare paid. It feels like every week I learn a new way people were ripping off taxpayers for billions. From X , 2 of 2

MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months $MDXG $SMTI https://stocktwits.com/news/equity/markets/mi-medx-sanara-merger-faces-fresh-regulatory-obstacle-smti-stock-falls-below-this-key-support-level-for-the-first-time-in-4-months/cZxKJ0GRBsM

$MDXG Reading between the lines of FDA request for more information on merger. The right people in government need there bribes first.

$MDXG Investment community may have missed this---$MDXG no longer a wound care company. Surgical multiples are much higher. Top line 2027 over 400m, at 5X multiple, that is 4 times current mkt cap.

$MDXG NEW: RFK Jr. says Medicare spending on wound care patches exploded from $200 million in 2019 to $14 billion last year: "It's all stolen." Bad actors billed Medicare billions by slapping the most expensive skin grafts on elderly and dying patients who didn't need them. "The doctors who prescribed them would get 6% of the sales cost. And so, they were incentivized to prescribe more expensive products. In Europe, they spend 35 cents a cubic inch. We were spending $135, and that went up to $2,000 a cubic inch." "So 2019, we were paying $200 million. Last year we spent 14 billion. All stolen. It's all stolen. And we were on track to spend 23 billion this year." "We put an end to it, and we now have driven that cost down to somewhere around a billion dollars." From X, 1 of 2

$MDXG doing a search on second requests from the FTC is disheartening. Stock priced as deal not happening.

$MDXG Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.01 down -106.67% YoY • Reported revenue of $62.28M down -45.23% YoY • MiMedx expects 2026 net sales of $250 to $260M, fourth-quarter Adjusted EBITDA sequentially higher than the third quarter, and longer-term annual net sales growth in the low double-digits with adjusted EBITDA margin above 20%.

$MDXG reports earnings today after the close. I used Stock Meadow’s earnings dashboard to review its history: MDXG has beaten EPS estimates in 5 of its last 8 reports. What are you watching for?

$MDXG reports earnings tomorrow after the close. I used Stock Meadow’s earnings dashboard to review its history: MDXG has beaten EPS estimates in 5 of its last 8 reports. Analysts expect EPS of $0.00. What are you watching for?

$MDXG earrings tmrw and none of the cheerleaders are posting ? why because crapper fckd up the acquisition ?

$MDXG told you something smells bad with this purchase crapper will Fck it up no doubt

$MDXG turned out to be the right move. Continue to lower that cost basis with the premiums I’m receiving

$MDXG acting like this deal is not going through that would not be good for Mdxg shareholders Crapper you better have crossed all the T’s and dotted the I’s